NATIONAL INSTITUTE FOR MEDICAL RESEARCH

Their core work

NIMR is Tanzania's leading public health research institution, conducting clinical trials and epidemiological studies on infectious diseases prevalent in sub-Saharan Africa — particularly HIV, hepatitis B, and vector-borne diseases. They provide critical African patient cohorts and field trial infrastructure for international vaccine development efforts and chronic disease management programs. Their work bridges laboratory immunology with community-level health interventions, making them an essential partner for any research requiring real-world clinical data from East Africa.

What they specialise in

How they've shifted over time

NIMR's early H2020 involvement (2016-2017) centered on HIV vaccine platforms and social science research on violence against women in Tanzania. From 2019 onward, their focus shifted decisively toward therapeutic vaccines for hepatitis B, chronic disease integration (hypertension/diabetes), and climate-linked vector-borne disease preparedness. This evolution shows a broadening from single-disease vaccine work toward a more comprehensive infectious and chronic disease portfolio with a growing climate-health dimension.

NIMR is expanding from pure infectious disease research toward the intersection of climate change and disease emergence, making them increasingly relevant for One Health and global health security consortia.

How they like to work

NIMR operates exclusively as a consortium partner — never as coordinator — which reflects their role as a field research provider rather than a project initiator. With 78 unique partners across 21 countries, they connect into large European-led consortia that need African clinical sites and patient populations. This makes them a reliable, low-friction partner: they know how to operate within large international teams and deliver their specific contribution without needing to drive the administrative side.

NIMR has collaborated with 78 unique partners across 21 countries, indicating deep integration into European health research networks despite being based in Tanzania. Their partnerships span major European universities and research hospitals that need African field sites for clinical validation.

What sets them apart

NIMR offers something most European research institutions simply cannot: direct access to large, diverse patient populations in East Africa for clinical trials on diseases that disproportionately affect the Global South. Their dual capability in both infectious disease immunology and community health systems research means they can support projects from laboratory-stage vaccine trials through to real-world health service delivery. For any consortium targeting tropical diseases, HIV, hepatitis, or climate-health interactions in Africa, NIMR is one of the few organizations that combines scientific credibility with on-the-ground operational capacity.

Highlights from their portfolio

• INTE-AFRICA
  Largest single funding (EUR 899K) — tackles the intersection of HIV and hypertension/diabetes, reflecting the growing chronic disease burden in Africa.
• TherVacB
  Ambitious therapeutic vaccine to cure hepatitis B (EUR 489K to NIMR), with NIMR providing patient cohorts and clinical trial capacity through 2026.
• PREPARE4VBD
  Represents NIMR's newest direction — cross-disciplinary vector-borne disease prediction combining disease ecology, molecular ecology, and climate modelling.